Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Applied Therapeutics Inc (APLT)

Applied Therapeutics Inc (APLT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,367
  • Shares Outstanding, K 26,237
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,580 K
  • 60-Month Beta 1.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade APLT with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.00
  • Most Recent Earnings -0.88 on 05/12/22
  • Next Earnings Date 08/11/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 295.53% ( -21.01%)
  • Historical Volatility 136.97%
  • IV Percentile 95%
  • IV Rank 38.16%
  • IV High 632.53% on 05/31/22
  • IV Low 87.57% on 08/24/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 58
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 3,577
  • Open Int (30-Day) 3,035

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.96
  • Number of Estimates 1
  • High Estimate -0.96
  • Low Estimate -0.96
  • Prior Year -0.99
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7277 +14.04%
on 06/28/22
1.5900 -47.81%
on 05/31/22
-0.7101 (-46.11%)
since 05/27/22
3-Month
0.7277 +14.04%
on 06/28/22
2.7300 -69.60%
on 04/06/22
-1.4401 (-63.44%)
since 03/29/22
52-Week
0.7277 +14.04%
on 06/28/22
22.2700 -96.27%
on 07/12/21
-20.6701 (-96.14%)
since 06/29/21

Most Recent Stories

More News
Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company...

APLT : 0.8299 (-6.82%)
Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company...

APLT : 0.8299 (-6.82%)
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline...

APLT : 0.8299 (-6.82%)
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

RDY : 54.98 (-0.56%)
AGLE : 0.5453 (-0.04%)
EYPT : 7.73 (-1.15%)
APLT : 0.8299 (-6.82%)
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition

Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.

ALNY : 143.90 (+1.20%)
NVS : 85.03 (+1.02%)
AGLE : 0.5453 (-0.04%)
APLT : 0.8299 (-6.82%)
Applied Therapeutics to Present at the UBS Global Healthcare Conference

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of...

APLT : 0.8299 (-6.82%)
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

RARE : 59.20 (+0.80%)
ABEO : 0.1850 (+2.78%)
AGLE : 0.5453 (-0.04%)
APLT : 0.8299 (-6.82%)
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study

Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.

HZNP : 82.38 (+0.84%)
AGLE : 0.5453 (-0.04%)
EYPT : 7.73 (-1.15%)
APLT : 0.8299 (-6.82%)
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement

Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.

SGEN : 180.00 (+0.86%)
AGLE : 0.5453 (-0.04%)
EYPT : 7.73 (-1.15%)
APLT : 0.8299 (-6.82%)
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia

The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.

EDIT : 12.58 (+1.04%)
AGLE : 0.5453 (-0.04%)
EYPT : 7.73 (-1.15%)
APLT : 0.8299 (-6.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Applied Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing drug candidates for unmet medical need. The company's product candidate consists of AT-001, for the treatment of Diabetic Cardiomyopathy; AT-007, for the treatment of Galactosemia and AT-003, for the treatment...

See More

Key Turning Points

3rd Resistance Point 1.1750
2nd Resistance Point 1.0529
1st Resistance Point 0.9718
Last Price 0.8299
1st Support Level 0.7686
2nd Support Level 0.6465
3rd Support Level 0.5654

See More

52-Week High 22.2700
Fibonacci 61.8% 14.0408
Fibonacci 50% 11.4988
Fibonacci 38.2% 8.9569
Last Price 0.8299
52-Week Low 0.7277

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar